Boehringer Ingelheim Pharmaceuticals Inc. and BioImage AS sign licensing deal on Redistribution® Technology

04-Feb-2005

BioImage A/S announced that it has signed a licensing agreement with Boehringer Ingelheim Pharmaceuticals Inc., granting it the freedom to use BioImage's Redistribution® technology in its drug discovery research. Financial terms were not disclosed.

The Redistribution® patent portfolio covers a broad range of methods aimed at studying intracellular signalling events. The Redistribution® technology enables high throughput screening on a number of drug discovery live cell screening applications, such as protein translocations, receptor internalizations, protein trafficking, secretions, etc. BioImage is presently out licensing the portfolio to a number of leading companies within the life science industry.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances